<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02671318</url>
  </required_header>
  <id_info>
    <org_study_id>43102815.0.0000.5505</org_study_id>
    <nct_id>NCT02671318</nct_id>
  </id_info>
  <brief_title>Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence</brief_title>
  <acronym>StopCMV</acronym>
  <official_title>Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence in Kidney Transplant Recipients (StopCMV: S=Sirolimus CMV= Cytomegalovirus)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital do Rim e Hipertensão</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital do Rim e Hipertensão</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cytomegalovirus is the most important opportunistic infection after kidney transplant, with
      increased in mortality, morbidity and higher costs of transplantation. Despite the favorable
      efficacy (lower acute rejection) results of the most worldwide used regime, tacrolimus,
      mycophenolate and prednisone, or the investigators local common regimen, tacrolimus,
      azathioprine and prednisone, this combinations are associated with higher incidence of
      cytomegalovirus infection, disease and recurrence.

      Namely, sirolimus use is associated with decreased risk of cytomegalovirus infection/disease,
      and there is not a prospective cohort to evaluate the conversion to sirolimus efficacy to
      decrease the cytomegalovirus infection recurrence.

      Given this, the investigators propose a study of their own initiative that attends local
      needs: evaluate the conversion to sirolimus efficacy in decrease the cytomegalovirus
      recurrence after kidney transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol is a prospective, randomized, single center, designed to evaluate incidence of
      cytomegalovirus recurrence infection/disease in two immunosuppressive regimens, after the
      first episode of cytomegalovirus: (1) conversion of azathioprine or mycophenolate to
      sirolimus, in a regimen wih low doses tacrolimus and prednisone; ( 2) Maintenance of the
      current regimen during the first episode of cytomegalovirus infection ( azathioprine or
      mycophenolate, in combination to tacrolimus or prednisone). Our hypothesis is that conversion
      from azathioprine or sodium mycophenolate to sirolimus, with low doses of tacrolimus, and
      prednisone results in lower recurrence of cytomegalovirus infection/disease in kidney
      transplant recipients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cytomegalovirus infection/disease recurrence</measure>
    <time_frame>One year</time_frame>
    <description>Cytomegalovirus infection/disease recurrence</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Cytomegalovirus Infections</condition>
  <arm_group>
    <arm_group_label>Drug conversion to sirolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug conversion to sirolimus: mycophenolate or azathioprine conversion to sirolimus, in a regimen with tacrolimus and prednisone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance of the current regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Maintenance of the current regimen: mycophenolate or azathioprine maintenance, in a regimen with tacrolimus and prednisone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug conversion to sirolimus</intervention_name>
    <description>Drug conversion to sirolimus: mycophenolate or azathioprine conversion to sirolimus, in a regimen with tacrolimus and prednisone.</description>
    <arm_group_label>Drug conversion to sirolimus</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maintenance of the current regimen</intervention_name>
    <description>Maintenance of the current regimen: mycophenolate or azathioprine maintenance, in a regimen with tacrolimus and prednisone.</description>
    <arm_group_label>Maintenance of the current regimen</arm_group_label>
    <other_name>Myfortic</other_name>
    <other_name>Immuran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult kidney transplant recipients &gt; 18 y.o.

          -  Kidney Transplant recipients, after the first episode of cytomegalovirus infection,
             using the current immunosuppressive regimen: azathioprine or mycophenolate, tacrolimus
             and prednisone.

        Exclusion Criteria:

          -  Re-transplant;

          -  Patients with any panel reactive antibody (PRA) equal to or above 50%, class I or
             class II;

          -  Acute rejection episode in the last 30 days, or episode &gt; 2A in the Banff criteria;

          -  GFR (MDRD) &lt; 40 ml/min;

          -  Proteinuria &gt; 0,5 g/l;

          -  Hemoglobin &lt; 10 g/l and/or leucocytes &lt; 4000 cels/mm3 and/or platelets &lt; 150.000
             cels/mm3;

          -  Triglycerides &gt; 500 mg/dl with or without use of fibrate;

          -  Cholesterol total &gt; 300 mg/dl with or without use of statin;

          -  Hepatic abnormalities;

          -  Significant periphery edema;

          -  Pulmonary abnormalities or breast x-ray abnormalities;

          -  Hyper sensibility to sirolimus formula;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geovana Basso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helio Tedesco Silva Junior, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claudia Rosso felipe, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leonardo V. Riella, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Brigham and Women's Hospital, US.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose O. Medina Pestana, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Nephrology Division, Hospital do Rim, Federal University of São Paulo, Brazil</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geovana Basso, MD</last_name>
    <phone>+55 11 50878000</phone>
    <email>geovana_basso@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital do Rim</name>
      <address>
        <city>São Paulo</city>
        <zip>04037-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geovana Basso, MD</last_name>
      <phone>+55 11 5087-8000</phone>
      <email>geovana_basso@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2016</study_first_submitted>
  <study_first_submitted_qc>January 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2016</study_first_posted>
  <last_update_submitted>August 15, 2016</last_update_submitted>
  <last_update_submitted_qc>August 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital do Rim e Hipertensão</investigator_affiliation>
    <investigator_full_name>Geovana Basso</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>cytomegalovirus</keyword>
  <keyword>sirolimus</keyword>
  <keyword>cytomegalovirus recurrence</keyword>
  <keyword>kidney transplant</keyword>
  <keyword>conversion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

